pipette
ENEnglish

A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency

Y. Huang, M. S. Nair, J. Yu, S. Chong, H. Hong, H. Mohri, H. Takata, B. D. Varco-Merth, A. Marenco, J. D. Lifson, L. Ndhlovu, A. Bowen, L. Trautmann, S. Vasan, T.-W. Chun, A. A. Okoye, D. D. Ho

PreprintUso en el mundo real

En palabras de los autores

Antiretroviral therapy suppresses HIV-1 replication but cannot eliminate the latent viral reservoir persisting in memory CD4 T cells. Existing latency reversal candidates have yet to achieve robust viral reactivation at tolerable doses. We engineered T4IL15{triangleup}, a bispecific biologic that selectively delivers IL-15 signaling to memory CD4 T cells, with minimal off-target stimulation. T4IL15{triangleup} reactivated latent virus in 94% (48/51) of clinical samples ex vivo, 75% (15/20) of administrations in HIV-1-infected and ART-suppressed humanized mice, and 100% (6/6) of SIV-infected and ART-suppressed rhesus macaques at doses well tolerated. We also found that off-target stimulation of non-CD4 cells hindered HIV-1 reactivation ex vivo. T4IL15{triangleup} provides a robust reactivation platform that could complement other reservoir-elimination strategies toward an HIV-1 cure.

Resultado principalEl resumen no menciona limitaciones.

Apareció: viernes, 9 de octubre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.06.757104